Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
University of Washington, Seattle, Washington.
JACC Cardiovasc Interv. 2018 Apr 9;11(7):677-689. doi: 10.1016/j.jcin.2018.01.247.
This study sought to develop a novel technique called bioprosthetic or native aortic scallop intentional laceration to prevent coronary artery obstruction (BASILICA).
Coronary artery obstruction is a rare but fatal complication of transcatheter aortic valve replacement (TAVR).
We lacerated pericardial leaflets in vitro using catheter electrosurgery, and tested leaflet splaying after benchtop TAVR. The procedure was tested in swine. BASILICA was then offered to patients at high risk of coronary obstruction from TAVR and ineligible for surgical aortic valve replacement. BASILICA used marketed devices. Catheters directed an electrified guidewire to traverse and lacerate the aortic leaflet down the center line. TAVR was performed as usual.
TAVR splayed lacerated bovine pericardial leaflets. BASILICA was successful in pigs, both to left and right cusps. Necropsy revealed full length lacerations with no collateral thermal injury. Seven patients underwent BASILICA on a compassionate basis. Six had failed bioprosthetic valves, both stented and stent-less. Two had severe aortic stenosis, including 1 patient with native disease, 3 had severe aortic regurgitation, and 2 had mixed aortic valve disease. One patient required laceration of both left and right coronary cusps. There was no hemodynamic compromise in any patient following BASILICA. All patients had successful TAVR, with no coronary obstruction, stroke, or any major complications. All patients survived to 30 days.
BASILICA may durably prevent coronary obstruction from TAVR. The procedure was successful across a range of presentations, and requires further evaluation in a prospective trial. Its role in treatment of degenerated TAVR devices remains untested.
本研究旨在开发一种名为生物瓣或原生主动脉瓣嵴有意撕裂术以预防冠状动脉阻塞(BASILICA)的新技术。
冠状动脉阻塞是经导管主动脉瓣置换术(TAVR)的一种罕见但致命的并发症。
我们使用导管电外科在体外撕裂心包叶片,并在台架 TAVR 后测试叶片张开情况。该程序在猪中进行了测试。BASILICA 随后提供给因 TAVR 而有冠状动脉阻塞高风险且不符合手术主动脉瓣置换术条件的患者。BASILICA 使用市售器械。导管引导通电导丝穿过并撕裂主动脉瓣的中心线。像往常一样进行 TAVR。
TAVR 使撕裂的牛心包叶片张开。BASILICA 在猪身上成功地进行了左、右嵴瓣,尸检显示完全长度的撕裂,没有侧支热损伤。7 名患者基于同情理由接受了 BASILICA。6 名患者的生物瓣失败,包括 1 名患者有原生疾病,3 名患者有严重主动脉瓣反流,2 名患者有混合主动脉瓣疾病。1 名患者需要撕裂左、右冠状动脉嵴瓣。BASILICA 后没有任何患者出现血流动力学障碍。所有患者均成功进行了 TAVR,没有发生冠状动脉阻塞、中风或任何重大并发症。所有患者均存活至 30 天。
BASILICA 可能持久地预防 TAVR 引起的冠状动脉阻塞。该程序在各种情况下均成功,需要进一步在前瞻性试验中进行评估。其在治疗退行性 TAVR 器械中的作用尚未得到测试。